Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hideko OhamaAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaTakeshi HatanakaJoji TaniKoichi TakaguchiMasanori AtsukawaEi ItobayashiTakashi NishimuraKunihiko TsujiKazuto TajiriToru IshikawaSatoshi YasudaHidenori ToyodaShinya FukunishiChikara OgawaSatoru KakizakiNoritomo ShimadaAtsushi NaganumaKazuhito KawataHisashi KosakaHidekatsu KurodaTomomitsu MatonoYutaka YataHironori OchiFujimasa TadaKazuhiro NousoAkihiro MorishitaNorio ItokawaTomomi OkuboTaeang AraiAkemi TsutsuiTakuya NaganoKeisuke YokohamaHiroki NishikawaMichitaka ImaiYohei KoizumiShinichiro NakamuraHiroko IijimaMasaki KaiboriYoichi HiasaTakashi Kumadanull nullPublished in: Cancer reports (Hoboken, N.J.) (2024)
The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.